Spread and Scale of an Electronic Deprescribing Software to Improve Health Outcomes of Older Adults Living in Nursing Homes: Study Protocol for a Stepped Wedge Cluster Randomized Trial

Marc-Eric Nadeau
Centre for Innovation and Research in Aging  https://orcid.org/0000-0002-4372-9462

Justine L. Henry
Centre for Innovation and Research in Aging

Todd C. Lee
McGill University Health Centre

Émilie Bortolussi-Courval
McGill University Health Centre

Carole Goodine
Horizon Health Network

Emily G. McDonald (✉ emily.mcdonald@mcgill.ca)
McGill University Health Centre

Study protocol

Keywords: Polypharmacy, deprescribing, older adults, long-term care, medication use, medication review, adverse drug event, nursing home, prescription check-up

DOI: https://doi.org/10.21203/rs.3.rs-527999/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Medication overload or problematic polypharmacy is a major problem causing widespread harm, particularly to older adults. Taking multiple medications increases the risk of potentially inappropriate medications (PIMs) and residents in long-term care (LTC) are frequently prescribed 10 or more medications at once. One strategy to address this problem is for the physician and/or pharmacist to perform regular medication reviews; however, this process can be complicated and time-consuming. With a prescription review, medications may be decreased, changed, or stopped altogether. MedReviewRx is a software that runs an analysis using deprescribing rules to produce a report to guide medication reviews addressing medication overload for residents in LTC.

**Methods:** This study will employ a mixed methods effectiveness-implementation hybrid type 2 study design. To measure effectiveness, a stepped wedge cluster randomized trial design is planned, which allows us to approximate a randomized clinical trial. Approximately 1000 residents living in LTC will be recruited from five facilities in New Brunswick. The study will begin with three months of baseline data on rates of deprescribing. Thereafter, every three months a new cluster will enter the intervention mode. The intervention consists of medication reviews augmented with the MedReviewRx software, which will be used by staff and clinicians in the facilities. The estimated study duration is 18-months and the main outcome will be the proportion of patients with one or more PIMs deprescribed (reduced/stopped or changed to a safer alternative) in the 90 days following a prescription review. The goal is to study the impact of MedReviewRx on medication overload among older adults living in LTC. In typical fashion of a stepped-wedge cluster randomized trial, each cluster acts as an internal control (before and after) as well as a control for the other clusters (external control). Qualitative data collected will include resident/caregiver attitudes towards deprescribing and semi-structured interviews with staff working in the long-term care homes.

**Discussion:** This study design addresses issues with seasonality and allows all clusters to participate in the intervention, which is an advantage when the intervention is related to quality improvement. This study will provide valuable information on PIM use, cost savings, and facilitators and challenges associated with medication reviews and deprescribing. This study represents an important step towards understanding and promoting tools to guide safe and rational reduction of PIM use among older adults.

**Trial registration:** NCT04762303, Registered February 21, 2021
https://clinicaltrials.gov/show/NCT04762303

**Administrative Information**

Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/).
## Title

Spread and scale of an electronic deprescribing software to improve health outcomes of older adults living in nursing homes: study protocol for a stepped wedge cluster randomized trial

## Trial registration (2a and 2b).

NCT04762303, Registered February 21, 2021 [https://clinicaltrials.gov/show/NCT04762303](https://clinicaltrials.gov/show/NCT04762303)

## Protocol version (3)

Protocol version 1.0 of April 28, 2021.

## Funding (4)

This research was financially supported by the Healthy Seniors Pilot Project, which is a $75 million three-year agreement between the Government of New Brunswick and the Public Health Agency of Canada, jointly led by the Government of New Brunswick's Department of Social Development and the Department of Health through the Aging Secretariat.

## Author details (5a)

1. Marc-Eric Nadeau, B.A.; Research Coordinator, Centre for Innovation and Research in Aging; MNadeau@ycc-cira.ca
2. Justine L. Henry, BSc., MSc.Kin; Director of Research, Centre for Innovation and Research in Aging; JHenry@ycc-cira.ca
3. Todd C. Lee MD MPH; Associate Professor of Medicine; Department of Medicine; McGill University Health Centre, Montreal QC, Canada; todd.lee@mcgill.ca
4. Émilie Bortolussi-Courval; CPN and Doctoral Student; Department of Experimental Medicine, McGill University, Montréal, QC, Canada; emilie.bortolussi-courval@mail.mcgill.ca
5. Carole Goodine, RPh, BSc (Pharm), ACPR, Pharm D; Clinical Pharmacy Manager, Fredericton Area, Horizon Health Network; Adjunct Professor, Faculty of Health Professions, College of Pharmacy, Dalhousie University. Carole.goodine@horizonnb.ca
6. Emily G. McDonald, MDCM MSc FRCPC; Associate Professor of Medicine; Department of Medicine; McGill University Health Centre, Montreal QC, Canada; Director- Clinical Practice Assessment Unit, emily.mcdonald@mcgill.ca

## Name and contact information for the trial sponsor (5b)

The Centre for Innovation and Research in Aging

100 Sunset Drive, Fredericton, New Brunswick E3A 1A3, Canada

1-506-444-3880 ext. 2560

MNadeau@ycc-cira.ca

## Role of sponsor (5c)

The funding source has no role in the study design; data collection, management, and analysis; interpretation of the data; writing the manuscript; or the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding sources. MedSafer was funded by the Centre for Ageing and Brain Health Innovation (CABHI), The Canadian Frailty Network and the Canadian Institutes for Health Research. Initial development of the Polypharmacy App developed (designed) for YCC was funded by CABHI, the New Brunswick Health Research Foundation, AGE-WELL and the New Brunswick Innovation Foundation.

## Background And Rationale (6a)
As highlighted by the Working Group on Medication Overload (1), problematic polypharmacy is an overwhelming problem for older adults. Nearly two thirds of community dwelling adults are taking five or more medications (2) and while most medications are prescribed to help people live longer, healthier lives, the more complex a medication regimen is, the more dangerous it becomes. With each added drug, the risk of an adverse drug event (ADE) increases (3), as well as the worsening of geriatric syndromes (4). A growing body of evidence suggests that patients and physicians may not recognize ADEs and additional new medications may be prescribed to treat an existing ADE (5). This so-called prescribing cascade further increases polypharmacy and the risk of ADEs. Aging itself is a risk factor for ADEs as changes in organ function, body weight, fat distribution, cognition, balance, function and drug receptor sensitivity all affect medication metabolism and side effects (6). Experts in geriatrics have published guidelines and lists of medications to be avoided or used cautiously in older adults (7–9). These medications are often referred to as potentially inappropriate medications or PIMs. PIMs are medications associated with a high risk of ADEs when administered to older adults, and may be of uncertain or no clinical benefit (10). Continued use of PIMs in later life, further increases the risk of ADEs associated with polypharmacy in older adults. Furthermore, as highlighted in a 2018 systematic review, there is a significant association between an increased number of medications and frailty, which is associated with an increased risk of adverse events in older adults (11).

Older adults living in nursing homes are at a particularly high risk of polypharmacy and ADEs as they are frail and often take ten or more medications (2). Some of these medications increase the risk of falls, fractures, kidney injury, bleeding, and death. Costs to the healthcare system from polypharmacy is very high and stem from emergency department visits, hospital admissions, and direct and indirect drug costs. As such, strategies to address polypharmacy are needed. One approach is the process of deprescribing, whereby a prescriber or pharmacist establishes the full list of medications a patient is taking and contextualizes them for the individual patient (12). Based on the medical history, a measure of frailty, and the patient and/or caregiver’s values or preferences, safer classes of medications are selected, doses may be decreased, and medication may be discontinued (12). This process can be thought of as a "prescription check-up".

While deprescribing may be effective for stopping PIMs, manually reviewing all drugs and cross referencing them with patient conditions and lists of inappropriate drugs in older adults requires an expert command of the literature and is time-consuming. In many Canadian provinces nursing home medication reviews are mandatory, however there are no consistent guidelines for the reviews and therefore existing processes often result in medications being re-prescribed without documentation of a clear rationale or reassessment. Studies in acute care hospitals have demonstrated that electronic decision support can facilitate the process of deprescribing and augment the proportion of patients with one or more PIM (potentially inappropriate or problematic) medications stopped upon discharge from the hospital (13). More studies looking at electronic tools for deprescribing in nursing homes are needed to determine if an investment on the part of the government into a software that supports deprescribing is warranted.
An electronic decision support tool for deprescribing called MedSafer has been studied in the Canadian acute care context. MedSafer augmented the proportion of patients who were discharged from the hospital with one or more PIMs deprescribed as compared to usual care (13). New Brunswick (NB) has the highest proportion of older adults compared to other provinces in Canada. In NB, 20.8% of the population is over 65 years of age and this is expected to increase to 31.3% by the year 2038 (14). Strategies to promote regular prescription check-up are needed to reduce polypharmacy in the setting of LTC. For this study, MedSafer researchers partnered with the Centre for Innovation and Research in Aging (CIRA) at York Care Centre (YCC) to improve a previously developed web-based application (Polypharmacy App) that allowed prescribers in New Brunswick Nursing Homes (NBNHs) to visualize MedSafer deprescribing reports on a desktop computer or tablet. The polypharmacy App, called MedReviewRx, will be implemented in a number of NBNHs.

Research questions

1. Is the MedReviewRx App developed at YCC, in Fredericton NB, easy to use, does it provide useful information, and does it reduce the time needed to conduct a medication review in other NBNHs?
2. How often do nursing home health care providers log into the MedReviewRx App, and how often does this action result in a prescription check-up (review and deemed appropriate or review and medication change)?
3. What are the challenges to implementing the MedReviewRx App in other NBNHs and what improvements are required for widespread use of the MedReviewRx App?
4. What is the impact of the MedReviewRx App on deprescribing PIMs and associated adverse events in NBNHs?

Objectives (7)

To embed software enabled deprescribing in five NBNHs using MedReviewRx, an App containing MedSafer recommendations, in order to study the effectiveness at deprescribing PIMs in LTC, along with feasibility of use.

Trial design (8)

This is a hybrid type 2 effectiveness-implementation design for quality improvement research that will make use of mixed methods of evaluation. Implementation consists of using MedReviewRx. Effectiveness analysis consists of measuring the impact of the MedReviewRx on PIMs. Exploratory surveys (the mixed methods component of the study) which look at qualitative and quantitative user feedback and patient and caregiver attitudes about deprescribing will be used to explain study findings. Informal feedback, surveys and semi-structured interviews will be used to examine user experience with MedReviewRx. The Revised Patient Attitude Towards Deprescribing (rPATD) questionnaire “older adult” version for the patients and a “caregiver” version for family members/substitute decision makers will be used to describe patient and family member attitudes about deprescribing medications.
Intervention description (11a)

Estimated study duration is 18 months, and the effectiveness component of the study will use a deployment strategy which approximates a Stepped-Wedge Cluster-Randomized Trial (SW-CRT). This design has many advantages and is considered the most robust type of study design for pragmatic quality improvement interventions. Each cluster will contribute a control period. Subsequently, at each of 3 pre-defined time periods, one cluster will be randomly assigned to transition from control to intervention. In this way, all clusters act as an internal control (before and after) as well as a contemporaneous control for the other clusters (external control). The study is composed of three clusters and each cluster contains the following number of beds: Cluster A 218, Cluster B 314, and Cluster C 272.

Criteria for discontinuing or modifying allocated interventions (11b)

There is no planned interim analysis as the intervention is considered safe and best practice. The study will be analyzed according to the intention to treat principle.

Strategies to improve adherence to interventions (11c)

We will provide training for the software users, along with memos and email remainders about the study during the intervention phase. Ultimately the decision to use the software will up to the individual prescriber as this is a pragmatic intervention to study the real-world effectiveness of making the software available for use in the LTC homes.

Relevant concomitant care permitted or prohibited during the trial (11d)

All usual care received by the participant is allowed to continue during the trial.

Provisions for post-trial care (30)

Participants in the trial will continue to receive usual care in the LTC home post trial completion.

Sample size (14)

Based on the Canadian Institute for Health Information’s report, titled “Drug Use Among Seniors in Canada, 2016”, we expect that about 70% will be taking one or more PIMs. This yields an average cluster size of 175 for patients with at least 1 PIM. Uptake of deprescribing using the MedSafer report in acute care studies ranges from 8-25% (13) over usual care. Conservatively, we think we can increase the proportion of patients with 1 or more PIM deprescribed from a baseline rate of 10% to 20% (absolute increase of 10% or a number needed to treat of 10). Using the Shiny CRT calculator (15) we estimate that we will have at least 72% power to detect this difference under assumptions of cluster autocorrelation of 0.8 and a within period intra-cluster correlation (ICC) 0.05. This increases to 96% power if the ICC is 0.02.

Recruitment (15)
Nursing homes may experience 20 to 30% patient turnover each year due to deaths, therefore the total number of nursing home residents who have at least one interRAI LTCF assessment during the study period is approximately 1000. For the purposes of analysis, only the initial closed cohort will be included in the study. New residents will not be analyzed in the current study. All homes have agreed to participate in the study and an individual waiver of consent has been granted by the Horizon Health Network Research Ethics Board.

**Sequence generation (16a)**

Computer-generated random numbers were used in order to generate the allocation sequence of the clusters.

**Concealment mechanism (16b)**

Study sites are not aware of which clusters they are assigned to and will only be made aware that they are entering into intervention mode approximately four-weeks prior, to allow for training on the use of the software.

**Implementation (16c)**

The principal investigator (EGM) of the study generated the allocation sequence. Participants are automatically enrolled in the study and assigned to the intervention when the targeted nursing homes agree to take part in the study.

**Who will be blinded (17a)**

The study investigators and analyst will be blinded to the intervention status at the time of outcome adjudication. Prescribers cannot be blinded as the intervention is the use of a computer software.

**Procedure for unblinding if needed (17b)**

There is no procedure for unblinding (does not apply to the trial design).

**Plans for assessment and collection of outcomes (18a)**

Each study site will appoint a site contact to load information into MedReviewRx and to communicate with the study team. The nursing home site contact or designate(s) will be e-mailed a Nursing Home Site Assessment Questionnaire for completion prior to project implementation. The purpose of this questionnaire is to determine information about the nursing home including workflow, structure of medication reviews, physician, pharmacy and nursing support. This information will be used to inform implementation and determine where MedReviewRx fits into the workflow. Study sites will also receive an implementation toolkit containing a user manual, instructions on how to use the Momentum extract report, a research study PowerPoint presentation, template for Staff/Crew Meeting “huddles”, sample announcement of study frequently asked questions and a list of deprescribing resource websites. The
CIRA research manager or designate will review the Nursing Home Site Assessment Questionnaire and Toolkit resources with the study site contact. If a nursing home site is not completing section N1 (List of all medications) of the interRAI LTCF assessment, a research assistant will be trained to enter this information for the study site.

The study will begin with a minimum three-month control phase. During the control phase, MedReviewRx will not be accessible to healthcare professionals at the nursing homes. This serves to obtain baseline deprescribing levels for each nursing home. Every three months thereafter, a cluster of nursing homes will enter intervention mode.

During the control phase, nursing home residents and their families or substitute decision makers will be recruited to complete a survey to explore patient attitudes about deprescribing in this NB study population. The rPATD questionnaire “older adult” version will be provided to nursing home residents and the “caregiver” version will be provided to family members and substitute decision makers. Survey questions will be entered in Lime survey to promote electronic completion whenever possible. A recruitment poster will be displayed at study sites and a recruitment communication will be sent to family members and substitute decision makers identified in the resident’s admission package. Paper copies will also be available from the study site contact. Residents and family members who ask nursing home staff about the survey will have their contact information forwarded to the CIRA research manager to answer questions and obtain verbal consent to have a survey e-mailed to them. If email is not available, a research assistant will contact the participant to administer the survey over the phone. Study site contacts may also distribute paper copies of the surveys if requested and permitted by the study site.

During the control phase, health care providers and study site staff will be recruited to register for MedReviewRx. A recruitment communication will be sent by e-mail and placed in study site mailboxes. Study recruitment will also be encouraged at interdisciplinary nursing home meetings such as Pharmacy and Therapeutics and Medical Advisory Committee meetings. User training will be provided by the study site contact or designate as determined by the site-specific implementation plan. Nursing home site contacts will participate in an interview to evaluate MedReviewRx implementation. Implementation interviews will be conducted within the first 3 months of the site intervention phase.

During the intervention phase, MedReviewRx will be made available to nursing homes with the understanding that it will be used to facilitate medication reviews and prescription check-ups. MedReviewRx provides clinicians with access to individualized and prioritized deprescribing information from MedSafer which:

A) Identifies PIMs.

B) Explains why the medication is potentially inappropriate.

C) Provides instructions on how to safely stop/taper the medication.
D) Links to patient informational brochures with non-pharmacologic interventions and rationale for deprescribing from the Canadian Deprescribing Network

Nursing homes will also have the option to print MedSafer deprescribing reports from MedReviewRx for clinicians who do not have computer access or who choose not to register to use MedReviewRx. If reports are printed, they will be placed in a binder for the prescriber to sign and date indicating that they have read the report. Prescribers and nursing home staff will be encouraged to write feedback directly on the report if they wish too. To assess the proportion of reports that were read, and feedback provided on the reports, signed reports will be kept in a locked cabinet for research assistants to collect. If visitor restrictions are in place, the study site contact will gather signed reports, place them in a sealed envelope(s) and send them to the CIRA research manager using a courier method that can be tracked and requires a sending signature and signature of receipt.

Clinicians will review deprescribing opportunities (electronically or via a paper report) and determine if medications can be tapered or stopped. Medication changes are discussed with the resident or substitute decision maker as part of usual care. This process will not change with the implementation of MedReviewRx. If the prescriber decides to alter a medication based on the deprescribing opportunities provided by MedSafer and their expert knowledge, the prescriber will do so in the same manner as they did prior to implementation of MedReviewRx, and discussion with the resident and/or substitute decision maker will occur according to the process in place at each nursing home.

During the intervention phase, an analysis of deprescribing opportunities will be conducted by MedSafer once every 3 months for each resident in the nursing home. Results will be stored in the MedReviewRx system to be accessed at any time.

Patients who die or are hospitalized will be censored from the study.

MedReviewRx has been designed to have Administrator accounts and Clinician accounts which restrict access according to user function. Study site contacts (or site designate) will load data into MedReviewRx using the Administrator function. Prescribers (physicians and nurse practitioners) and pharmacists will be provided with Clinician accounts. Clinicians will only access MedReviewRx records for patients under their care. MedReviewRx registration has been designed to restrict nursing home staff access to residents at their site only. Prescriber and pharmacist access will be restricted to study sites where they practice. MedReviewRx access will be audited by the CIRA research manager or designate.

User feedback on MedReviewRx and MedSafer deprescribing information will be solicited from prescribers, pharmacists and nursing home staff throughout the study using surveys. Surveys may be completed via Lime Survey, on paper or by telephone. Three surveys will be distributed by e-mail to registered MedReviewRx users as well as other study site prescribers, pharmacists and nurses who may have access to printed reports from MedReviewRx. Paper copies of the surveys will also be available at the study site nursing units. A MedReviewRx user feedback survey will be distributed at the end of the first and third quarter of the intervention and an acceptability and feasibility survey will be distributed at the
end of the study. Paper copies of completed surveys will be collected by the study site contact, placed in a sealed envelope(s) and sent to the CIRA research manager using a courier method that can be tracked and requires a sending signature and signature of receipt. Courier costs will be paid for by CIRA. MedReviewRx users will be provided with a study e-mail which they may use to submit feedback and questions at any time throughout the study. Informal feedback received by email from users will be reviewed and actioned by the CIRA research manager or designate. E-mail feedback will be documented anonymously in an excel spreadsheet and reported to the study principal investigators within 1 week of receipt to determine if tasks need to be submitted to the technical team for software updates. Rapid cycle improvements in usability of the system and MedSafer output will be made based on survey results and informal feedback.

Informal feedback written on printed MedSafer reports will be documented in an excel spreadsheet and included in the analysis of qualitative feedback provided by survey and interview.

Frequency of MedReviewRx use will be measured electronically by counting the number of times a user accesses their account.

Overall experience with the research project will be evaluated using semi-structured interviews conducted at the end of the intervention period.

Sampling procedures

Convenience sampling was used to select nursing homes for the study. NBNH administrators and directors of nursing were contacted by email to determine interest in study participation.

Convenience sampling will also be used to recruit health care providers, older adults and family members of older adults from study nursing homes. A recruitment poster for resident and family member surveys will be posted in study nursing homes and a communication will be sent to families and substitute decision makers by regular mail or e-mail using the study site contact list. Health care providers and study site staff will be recruited to register for MedReviewRx by placing written recruitment notices in their nursing home site mailbox and/or by email. All pharmacists, nurses, nurse practitioners and physicians providing care at the participating nursing home will receive recruitment emails for MedReviewRx feedback surveys. Members of healthcare teams at the study sites will be recruited to participate in interviews to explore overall experience with the research project.

Variables under investigation include:

A) Patient demographics (date of admission to LTC, age, sex, gender, nursing home identifier, medical and psychiatric conditions documented in the interRAI LTCF assessment, and date of discharge from LTC if applicable).

B) Medication use data: absolute number of medications, number of PIMs, proportion of all medications that are PIMs, and type of deprescribing opportunities identified (PIMs that are high risk, intermediate risk
or of little added value).

C) Safety data: death, fracture, fall, use of restraints, transfer to hospital, change in functional status based on interRAI activities of daily living (ADL) scores. Episodes of delirium based on responses to questions in Section C of the interRAI LTCF assessment form (periodic disordered thinking or awareness and acute change in mental status from a person's usual functioning).

D) Health care provider experience with MedReviewRx and MedSafer deprescribing information as described in the user feedback surveys and the acceptability and feasibility survey.

E) Nursing Home evaluation of the implementation toolkit.

F) Patient and caregiver attitudes about deprescribing.

**Plans to promote participant retention and complete follow-up {18b}**

Participants are automatically enrolled when targeted nursing homes agree to take part in the study.

**Data management {19}**

Patient demographics and safety data is entered in the interRAI LTCF assessment software by nursing home staff as part of usual care. Medication information will be obtained from nursing home MARs and entered in section N1 of the interRAI LTCF assessment software by nursing home staff or a trained research assistant. Research assistants who enter medication data will receive training on how to enter medication information into Momentum LTCF assessment software. Patient demographics, medication use, and safety data will be extracted from the LTCF interRAI assessment software and loaded into MedReviewRx by the study site contact (or designate) at each nursing home.

**Confidentiality {27}**

MedReviewRx will de-identify the data and transmit data sets to MedSafer. Multiple safeguards have been put in place to protect this data. Data sets do not contain patient specific information. Age is transmitted rather than date of birth, and a unique identifier is assigned to each patient data set. MedSafer is unable to identify patients however the unique identifier allows MedReviewRx and MedSafer applications to anonymously communicate about specific patients through an application programming interface (API). Data sets will be analyzed by the MedSafer software program. Files containing one or more targeted PIM and associated triggering condition(s) will have deprescribing opportunities flagged and returned to MedReviewRx. MedReviewRx will link the unique identifier to the correct nursing home patient and translate the MedSafer analysis into an output for review by their health care team. A message will also be displayed by MedReviewRx if there are no deprescribing opportunities identified for a data set. MedReviewRx transmits and stores data using a secure web-based system which was designed by Missing Links Technology (MLT) under the supervision of the New Brunswick Community College (NBCC). The MedReviewRx system safeguards personal health information (PHI) that it collects,
processes and disseminates within trusted and authorized circles of care and ensures the confidentiality and privacy of the PHI. Each study site using MedReviewRx has site specific policies and procedures with respect to privacy and confidentiality of PHI.

Data from User Feedback Surveys and Acceptability and Feasibility Surveys and survey responses collected from the rPATD questionnaires completed via Lime Survey will be extracted into excel sheet format. Survey data collected from paper surveys or telephone surveys will be entered into the excel database by a research assistant. Research assistants will be provided with templates for excel data entry and trained on how to complete the template. A minimum of 5% of the research assistant data entry will be audited for accuracy and completeness by the CIRA research manager or designate. Interview data will be recorded and transcribed verbatim by research assistants. Interview recordings will be deleted after transcripts have been validated. Study data (PIMs, survey responses, interview transcripts) will be stored in password protected, members only secure cloud-based study sites hosted within Canada. Study data will only be accessible to the study research team and the CIRA research manager. On study closure, after final data analysis is completed, study data will be downloaded to a password protected study folder on the YCC secure network and the cloud-based study site will be permanently deleted. Study data will be stored for 7 years and then destroyed in accordance with YCC/CIRA policies and procedures.

**Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use (33)**

No biological specimens were collected as part of this trial.

**Data analysis plan**

This mixed methods study will employ both qualitative and quantitative data analysis.

**Statistical methods for primary and secondary outcomes (20a)**

Analysis of the primary outcome will be conducted using the stepped wedge function in Stata v. 15 or a similar statistical program.

**Interim analyses (21b)**

There is no planned interim analysis.

**Methods For Additional Analyses (E.g. Subgroup Analyses) (20b)**

Subgroup analyses will be conducted using the stepped wedge function in Stata v.15 or a similar statistical program.

**Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data (20c)**
The study will be analyzed according to the intention to treat principle. All data that is collected is from the LTC inteRAI form and data entry is mandated by the province. We do not expect missing data.

**Plans to give access to the full protocol, participant level-data and statistical code (31c)**

The full protocol will be published online and anonymize participant level data will be made available upon request to the principal investigator (EGM). Data will be made available for 1 year following the publication of the primary manuscript from the trial.

**Outcomes (12)**

The primary outcome of interest is:

1) Impact of MedReviewRx on the proportion participants with one or more PIMs deprescribed, compared to usual care.

**Impact on PIMs**

The impact on PIMs will be determined by the proportion of nursing home residents who have one or more PIMs reduced or stopped after the treating physician receives a MedSafer report. This outcome will be measured by using unique identifiers to compare medication data from sequential interRAI data sets. PIMs identified in the baseline data set, will be compared with the next data set (3 months later) transmitted with that unique identifier to determine if any of the PIMs has been stopped (no longer listed) or if a PIM dose has been reduced. This process will continue for the study duration. All statistical comparison will be performed via STAT v 15 (or equivalent) and the stepped wedge function will be used for the primary outcome (proportion of patients with one or more PIMs deprescribed over the study period).

At the end of the study, subgroup analysis will be conducted on the PIM data to explore PIM use based on sex, gender and geographic location.

**Secondary outcome:**

1. User experience with MedSafer reports and MedReviewRx.

**User experience**

User experience with MedSafer reports and MedReviewRx will be measured using survey responses as well as described through interview data and informal feedback received by the study team. Several outcomes will be studied: how satisfied the user is with the App, including how helpful they find it, the added knowledge from a MedSafer report for the prescriber, how likely the prescriber is to continue using the App once the study is over. Survey responses will be analyzed based on the following themes: Value & benefits, scientific content, and user satisfaction. Interview data will be thematically analyzed (16).
Other secondary outcomes to be examined at 90-days following each intervention cycle include:

A) Safety data: death, fracture, fall, use of restraints, transfer to hospital, and change in functional status based on interRAI activities of daily living (ADL) scores. Episodes of delirium based on responses to questions in Section C of the interRAI LTCF assessment form (periodic disordered thinking or awareness and acute change in mental status from a person's usual functioning).

Tertiary outcomes include:

1. Cost savings analysis related to cost saved from medications (actual price of the medication as well as dispensing fees) balanced with the cost of deployment of MedSafer including maintaining the program with updates and user support.
2. Patient and family attitudes about deprescribing will be reported using survey responses collected from the rPATD questionnaires.

Project evaluation

This project will be evaluated locally at each participating nursing home site to determine usability, impact on workflow, time commitment, and value added. Qualitative and quantitative user feedback as described above will be used to explain study findings.

Patient and family attitudes about deprescribing will be described descriptively using survey responses collected from the revised rPATD questionnaires.

An analysis will be conducted to determine strategies to inform widespread deployment, nursing home evaluation of the implementation toolkit, prescribing patterns based on geographic area and overall change in PIM use. System level impact on cost-savings and cost avoidance of adverse effects will be projected.

Study setting (9)

A subset of nursing homes in New Brunswick have agreed to participate in the study. Study participants will include health care providers and nursing home staff at participating nursing homes, as well as the older adults who live in these nursing homes and their family members or substitute decision makers.

Our study represents a total 804 nursing home beds and will provide a sample of NBNH residents and health care providers in three urban centers representing both large and mid-size long term care facilities who conduct business in English, as well as one long term care facility being bilingual (English and French).

Eligibility criteria (10)

Inclusion criteria
Residents residing in one of the participating homes
Aged 65 years of age or older
Taking one or more PIMs (as identified by MedSafer)

Exclusion criteria for the secondary outcome of attitudes toward deprescribing:

- If both the patient and proxy are unable to complete the survey, the patient will be excluded from the survey component of the study.

Participant timeline {13}

1As this is a cluster-randomized controlled trial, allocation occurs at the cluster level.

2RPATD = Revised Patient Attitude Towards Deprescribing.

Who will take informed consent? (26a)

A waiver of informed consent for participation in the deprescribing aspect of the study was obtained from the research ethics board of the Horizon Health Network Research Ethics Board. Informed consent for participation in the survey component of the study will be obtained at the time of survey completion with a preamble prior to any survey completed.

Additional consent provisions for collection and use of participant data and biological specimens {26b}

Not applicable. No biological specimens will be collected as part of this trial.

Explanation for the choice of comparators {6b}

Deprescribing using MedReviewRx during the intervention phase will be compared with usual care (deprescribing when not using MedReviewRx) in the control phase.

Prescribers (physicians and nurse practitioners) and pharmacists providing care at the study nursing homes will be eligible to use MedReviewRx to conduct prescription check-ups for older adults under their care. Nursing home staff (unit clerks, administrators, interRAI coordinators and nurses) at the study site will be eligible to register to load LTCF assessment information into MedReviewRx and print MedSafer reports from the system for prescribers who do not use MedReviewRx. A designated contact person will be appointed by the Director of Nursing or designate at each nursing home. The study site contact will act as a liaison with the research study team and coordinate study site activities. Study site contacts will also complete a site assessment questionnaire at the beginning of the study and an interview within 3 months of initial MedReviewRx implementation. Prescribers, pharmacists, nurses and staff at study nursing homes will be recruited to complete surveys to evaluate the MedReviewRx system and MedSafer report information. At the end of the study site contacts, nursing home staff, prescribers, pharmacists and
| STUDY PERIOD | Allocation | Post-allocation | Follow-up Data | Close-out |
|--------------|------------|-----------------|----------------|-----------|
| TIMEPOINT    | 0          | Months 1-3      | Months 4-6     | Months 7-9 | Months 10-12 | Months 13-15 | Months 16-18 |
| ENROLMENT    |            |                 |                |           |               |               |               |
| Eligibility Screen | X             |                 |                |           |               |               |               |
| Informed Consent | X             |                 |                |           |               |               |               |
| CONTROL (C) INTERVENTION (I) | | | | | | | |
| Cluster 1    | C          | I               | I              | I          |               |               |               |
| Cluster 2    | C          | C               | I              | I          |               |               |               |
| Cluster 3    | C          | C               | C              | I          |               |               |               |
| ASSESSMENTS  |            |                 |                |           |               |               |               |
| Demographic Data | X             | X               | X              | X          | X             |               |               |
| Medication Data | X             | X               | X              | X          | X             |               |               |
| Safety Data  | X          | X               | X              | X          |               |               |               |
| Nursing Home Site Assessment Questionnaire | | | | | | | |
| RPATD$^2$ Questionnaire: Older Adult Version | | | | | | | |
| RPATD$^2$ Questionnaire: Caregiver Version | | | | | | | |
| User Feedback Survey | X             |                 | X              | X          |               |               |               |
| Acceptability & Feasability Survey | | | | | | | X |
| Implementation Evaluation Interview | | | | | | X | X |
| End Of Study Feedback Interview | | | | | | | X |
| DATA ANALYSIS | | | | | | X | X |
nurses will be recruited to participate in an interview to evaluate the program. Consent will be obtained for MedReviewRx users, interview and survey participants.

Adults aged 65 years or older who live at participating nursing homes and have had a quarterly interRAI LTCF assessment completed are eligible for MedSafer analysis. A waiver of patient consent was requested and approved to load patient data into MedReviewRx. InterRAI LTCF assessments are completed on admission to a NBNH, and every 3 months thereafter as a standard of care. Assessment data is collected by NBNHs electronically using Momentum software. Momentum has written a customized data extract report for this project. Patient demographics, medical conditions, medication information and safety monitoring data required for this study are extracted from the Momentum extract report and uploaded into MedReviewRx at the study site. MedReviewRx removes identifiable patient information and assigns a unique identifier to each person’s data set, anonymized data sets are encrypted and securely transmitted to MedSafer for analysis. The ability to download secondary interRAI assessment data on medical conditions, medication lists and safety data for each nursing home resident is essential to this research study. Without this information it will not be possible to calculate the proportion of PIMs used at the study sites, evaluate the impact of MedReviewRx on deprescribing at each site, or assess study safety endpoints. A waiver of consent is unlikely to adversely affect the welfare of individuals to whom the information relates as the information is already collected as part of usual care. Study researchers have conducted an analysis of the MedReviewRx system and appropriate measures have been taken to protect the privacy of individuals and to safeguard personal health information. It is impracticable to seek consent from all individuals to whom the secondary information relates as new nursing home residents are admitted regularly when previous residents are discharged or deceased, interRAI data is downloaded in batches by assessment date, and study endpoints require information on all residents in each study site. In addition to safeguarding information, the research team will enter into data sharing agreements with each study site to obtain permission for secondary use of information for this research study.

Adults aged 65 years or older who live at a participating nursing home during the study, and their family members or substitute decision makers will be recruited to participate in a survey to explore their attitudes on medication use and deprescribing. Posters will be placed in study nursing homes; the study will be promoted verbally at resident and family council meetings and a recruitment communication will be sent by e-mail or mail to family members identified as contacts and/or substitute decision makers in the resident’s admission documents. Consent will be obtained for survey completion.

**Materials**

1) Electronic documentation of medications and medical conditions in Momentum interRAI LTCF assessment software.

2) MedSafer software system for identifying PIMs.
3) A secure Cloud Service to store information. This will be obtained through a subscription from Canadian Web Hosting.

4) MedReviewRx, a system which extracts, de-identifies and transmits data between study nursing homes and MedSafer and provides an interface for viewing MedSafer outputs on mobile devices and computers.

5) Nursing Home Assessment Questionnaire

6) Implementation Toolkit

7) User Feedback Survey

8) Acceptability and Feasibility Survey

9) rPATD questionnaire “older adult” version for the patients and a “caregiver” version for family members and substitute decision makers.

10) Recruitment materials

**Composition of the coordinating centre and trial steering committee (5d)**

The Centre for Innovation and Research in Aging (CIRA) is acting as the coordinating centre. The Research Coordinator at CIRA, under it’s Executive Director, is in direct contact with all of the study sites participating in the trial in order to implement the intervention as intended. The Principal Investigators of the study are representing Horizon Health Network (HHN) and McGill University Health Centre (MUHC). CIRA, HHN and MUHC meet weekly or bi-weekly. The data management team is being represented by the NB Institute for Research, Data and Training (NB-IRDT) and is providing the statistical analysis.

**Composition of the data monitoring committee, its role and reporting structure (21a)**

Data is being monitored by the above entities CIRA, HHN, MUHC and NB-IRDT.

**Adverse event reporting and harms (22)**

Adverse events will be collected, assessed, reported and managed independently by each study site. There is no planned interim safety analysis.

**Frequency and plans for auditing trial conduct (23)**

Each site will have a site initiation visit to go over the study protocols as well as a closing visit at the end of the study. Data is routinely collected data in the electronic health record. Feedback from the end users is being solicited through surveys and small group interviews.
Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}

If any important protocol amendments take place, they will be communicated in writing, in an email format, to the relevant parties.

Dissemination plans {31a}

Trial results will be made available through publication in a peer-reviewed indexed journal. Study results will be disseminated via newsletters to the study homes and pertinent results of the study will be communicated to New Brunswick health officials.

Discussion

The goal of this project is to study the impact of MedReviewRx, an intervention designed to help address the issue of medication overload among older adults living in NBNHs. MedReviewRx allows health care providers (prescribers, pharmacists and nurses) in nursing homes to access MedSafer analysis on a tablet or laptop. Our mixed-methods study, employing both qualitative and quantitative data analysis, has been designed to measure two primary outcomes. Firstly, baseline prevalence of PIMs in study nursing homes in order to calculate the change in PIM use after MedReviewRx is implemented. The intervention will be tailored and adapted to each participating nursing home's existing administrative and management workflow. Secondly, user experience with MedSafer reports and MedReviewRx will also be explored as well as nursing home evaluation of the implementation process.

Our study will also measure two secondary outcomes. Primarily, we will measure sustainability by looking at the proportion of patients with one or more PIM reduced or stopped following each cycle. Secondarily, we will measure safety data by looking at events such as deaths, fractures, falls, use of restraints, transfers to hospital, change in functional status, transfers out of the institution, and episodes of delirium.

Last but not least for outcome measures, we will measure tertiary outcomes by doing a cost savings analysis related to cost saved from medications, balanced with the cost of deployment of MedSafer including maintaining the program with updates and user support. Moreover, we will also measure patient and family attitudes about deprescribing using survey responses collected from the rPATD questionnaires.

In terms of our study design, we adopted a SW-CRT design. This novel study design addresses issues with seasonality and allows all clusters to participate in the intervention, which is an advantage when the intervention is related to quality improvement, and is appropriate for this study in several ways (17). First, the SW-CRT design provides an opportunity for all participating nursing homes to get the intervention at different time-points during the intervention period. This is a relevant issue in the recruitment of the participating homes, which are resource-limited and busy in their day-to-day practice. Second, the design
is suitable for the research team, which, with its limited budget and manpower, would be compromised by 
rolling out the intervention to all the nursing homes at the same time while ensuring the quality of 
implementation. Third, the study design allows an estimation of the intervention effects using both a 
between- and within-cluster comparison, and is particularly used to evaluate the impact of the 
implementation of prediction models in clinical practice. This unidirectional crossover design combines 
elements of before-after studies with cluster randomization and is an efficient design that enables to 
derive a valid answer for the research question (18). Moreover, stepped-wedge trials are claimed by many 
researchers to have a statistical advantage over parallel cluster randomized trials (19). In the same 
direction, (20) state that for cluster randomized trials (CRTs), the stepped wedge design is far more 
efficient than the parallel group and ANCOVA design requires a substantially smaller sample size.

Challenges in conducting the study are currently being faced. Firstly, the present pandemic era created by 
the novel COVID-19 has deprived our participating sites of their usual financial and human resources, 
which were allocated to battle the virus. Some of our homes even faced an outbreak of the virus among 
their residents, which put a halt on their research operations in order to fully mobilize their resources. 
Because every site is in its own unique situation, guidance and support from the study team will be 
tailored individually to each of those sites. Secondly, it was brought to our attention that some nursing 
homes are not using a patient waiver upon admission for the use of secondary data. Even though that is 
a standard practice at YCC, where CIRA is housed, it is not a standard practice at all of our participating 
sites and, within a larger scope, at all of the NBNHs. For this reason, an amendment was submitted to the 
Horizon Health Network Research Ethics Board for a waiver of consent for using secondary data from all 
study sites.

In conclusion, this study will provide valuable information on PIM use as well as facilitators and 
challenges associated with medication reviews and deprescribing. We hope that this study will 
demonstrate that implementing MedReviewRx is feasible and acceptable to health care providers in 
NBNHs and that it results in a decreased PIMs and cost savings. This study is an important step towards 
understanding and promoting tools to guide safe and rational reduction in PIM use among older adults. 
We believe that MedReviewRx will be an efficient, user-friendly application that will be very useful to 
physicians, pharmacists and nurses and will greatly facilitate the deprescribing process.

**Trial Status**

Protocol version 1.0 of April 28, 2021. Recruitment will begin in August 2021 and is expected to be 
completed by August 2022. Follow-up will be complete as of November 2022.

The study is nearing the beginning of the intervention phase at the submission of this manuscript. Data 
analysis has not yet started. Detailed statistical analysis plan will be complete prior to subject enrolment.

**Abbreviations**
ADE: adverse drug event

API: application programming interface

PIM: potentially inappropriate medications

LTC: long-term care

LTCF: Long-Term Care Facilities

NB: New Brunswick

NBNHs: New Brunswick nursing homes

CIHI: Canadian Institute for Health Information

DINs: drug identification numbers

CIRA: Centre for Innovation and Research in Aging

YCC: York Care Centre

MARs: Medication Administration Records

SW-CRT: Stepped-Wedge Cluster-Randomized Trial

CRTs: cluster randomized trials

rPATD: Revised Patient Attitude Towards Deprescribing

MLT: Missing Link Technologies

NBCC: New Brunswick Community College

Declarations

- Ethics approval and consent to participate

This study was approved by the Horizon Health Network Research Ethics Board.

- File #: 101109
- Event #: 21783
- RS #: 2020-2960
- Consent for publication
No identifying images or other personal or clinical details of participants are presented that compromise anonymity.

- **Availability of data and materials**

Study protocol will be made available 1 year following the publication of the primary manuscript from the trial.

- **Competing interests**

Dr. McDonald and Dr. Lee are co-owners of the MedSafer software that powers the application in this study and jointly own the company MedSafer CORP. Both physicians also receive salary support from the Fond de recherche santé Québec.

- **Funding**

This research was financially supported by the Healthy Seniors Pilot Project, which is a $75 million three-year agreement between the Government of New Brunswick and the Public Health Agency of Canada, jointly led by the Government of New Brunswick's Department of Social Development and the Department of Health through the Aging Secretariat. The funding source has no role in the study design; data collection, management, and analysis; interpretation of the data; writing the manuscript; or the decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding sources. MedSafer was funded by the Centre for Ageing and Brain Health Innovation (CABHI), The Canadian Frailty Network and the Canadian Institutes for Health Research. Initial development of the Polypharmacy App developed for YCC was funded by CABHI, the New Brunswick Health Research Foundation, AGE-WELL and the New Brunswick Innovation Foundation.

- **Authors' contributions**

EGM and TCL developed the methodology of the study. The study idea conception and designs were by CG and EGM. The initial draft was by EGM, CG, JH and MEN. All authors were involved in the revisions of the paper. The authors read and approved the final manuscript.

**References**

1. Eliminating Medication Overload. A National Action Plan - Lown Institute [Internet]. [cited 2021 Mar 26]. Available from: https://lowninstitute.org/reports/eliminating-medication-overload-a-national-action-plan/.

2. Canadian Institute for Health Information. Drug Use Among Seniors in Canada, 2016. Ottawa: CIHI; 2018. p. 69.
3. Maher RL, Hanlon JT, Hajjar ER. Clinical Consequences of Polypharmacy in Elderly. Expert Opin Drug Saf [Internet]. 2014 Jan [cited 2021 Apr 12];13(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864987/.

4. Kim J, Parish AL. Polypharmacy and Medication Management in Older Adults. Nurs Clin North Am. 2017 Sep;52(3):457–68.

5. Brath H, Mehta N, Savage RD, Gill SS, Wu W, Bronskill SE, et al. What Is Known About Preventing, Detecting, and Reversing Prescribing Cascades: A Scoping Review. J Am Geriatr Soc. 2018 Nov;66(11):2079–85.

6. Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016 Feb;7(1):11–22.

7. By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015 Nov;63(11):2227–46.

8. O'Mahony D, O'Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213–8.

9. Choosing Wisely Canada [Internet]. Choosing Wisely Canada. [cited 2021 Apr 12]. Available from: https://choosingwiselycanada.org/.

10. Gallagher P, Barry P, O'Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007 Apr;32(2):113–21.

11. Gutiérrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero Á, Inzitari M, Martínez-Velilla N. The relationship between frailty and polypharmacy in older people: A systematic review. Br J Clin Pharmacol. 2018 Jul;84(7):1432–44.

12. Thompson W, Farrell B. Deprescribing. What Is It and What Does the Evidence Tell Us? Can J Hosp Pharm. 2013;66(3):201–2.

13. McDonald E, Wu P, Rashidi B, Forster A, Huang A, Pilote L, et al. The MedSafer Study: A Controlled Trial of an Electronic Decision Support Tool for Deprescribing in Acute Care: THE MEDSAFER STUDY. Journal of the American Geriatrics Society. 2019 Jun 27;67.

14. AnAgingStrategyForNB.pdf [Internet]. [cited 2021 Apr 12]. Available from: https://www2.gnb.ca/content/dam/gnb/Departments/sd-ds/pdf/Seniors/AnAgingStrategyForNB.pdf.

15. Hemming K, Kasza J, Hooper R, Forbes A, Taljaard M. A tutorial on sample size calculation for multiple-period cluster randomized parallel, cross-over and stepped-wedge trials using the Shiny CRT Calculator. International Journal of Epidemiology. 2020 Jun 1;49(3):979–95.

16. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006 Jan 1;3(2):77–101.

17. Kim H, Park Y-H, Jung Y, Choi H, Lee S, Kim G-S, et al. Evaluation of a technology-enhanced integrated care model for frail older persons: protocol of the SPEC study, a stepped-wedge cluster randomized trial in nursing homes. BMC Geriatrics. 2017 Apr 18;17(1):88.
18. van der Sluijs R, Fiddelers AAA, Waalwijk JF, Reitsma JB, Dirx MJ, den Hartog D, et al. The impact of the Trauma Triage App on pre-hospital trauma triage: design and protocol of the stepped-wedge, cluster-randomized TESLA trial. Diagnostic and Prognostic Research. 2020 Jun 18;4(1):10.

19. Barker D, D’Este C, Campbell MJ, McElduff P. Minimum number of clusters and comparison of analysis methods for cross sectional stepped wedge cluster randomised trials with binary outcomes: A simulation study. Trials. 2017 Dec;18(1):119.

20. Woertman W, de Hoop E, Moerbeek M, Zuidema SU, Gerritsen DL, Teerenstra S. Stepped wedge designs could reduce the required sample size in cluster randomized trials. J Clin Epidemiol. 2013 Jul;66(7):752–8.